Johnson Fistel Investigates Simulations Plus, Inc. (SLP) After Revenue Guidance Cut, Impairment Charge, and Auditor Dispute

Simulations Plus faces severe financial and governance setbacks with little near-term recovery in sight.

What the company is saying

The company’s core narrative is not directly presented in this announcement; instead, the story is told through a law firm’s investigation into Simulations Plus, Inc. and its executives for potential securities law violations. The specific claims highlighted are the company’s sharp downward revision of full-year fiscal 2025 revenue guidance—from $90–$93 million in April to $76–$80 million in June—alongside a massive third-quarter net loss of $67.3 million, which includes a $77.2 million non-cash impairment charge. The announcement frames these developments as consequences of market uncertainties affecting pharmaceutical and biotech customers, such as budget cuts, project cancellations, and delays, but provides no granular breakdown or quantified impact for these attributions. The press release emphasizes the sequence of negative events: revenue guidance cuts, large losses, stock price collapses, and the abrupt dismissal of the company’s auditor, Grant Thornton LLP, who publicly stated that issues with segment reporting and internal controls were unresolved. Notably, there is no commentary from Simulations Plus management, no operational updates, and no forward-looking business plan or corrective action disclosed—these omissions are glaring and suggest either a lack of strategy or a reluctance to communicate under legal scrutiny. The tone is strictly factual and negative, with no attempt to soften the blow or reassure investors. The only individuals named are Frank J. Johnson, Esq. (presumably a principal at Johnson Fistel, the investigating law firm) and James Baker (Investor Relations), but neither is presented as a company executive or institutional investor; their roles are procedural, not strategic. This narrative fits a defensive, damage-control posture rather than proactive investor relations, and marks a sharp break from any prior messaging that might have emphasized growth or stability. There is no evidence of a shift toward transparency or accountability—if anything, the lack of company voice and the auditor’s unresolved concerns point to deepening governance issues.

What the data suggests

The disclosed numbers paint a picture of rapid financial deterioration. Simulations Plus cut its full-year fiscal 2025 revenue guidance by roughly 15% in just over two months, from $90–$93 million (April 3, 2025) to $76–$80 million (June 11, 2025), signaling a significant and sudden loss of business momentum. The third-quarter net loss of $67.3 million is staggering, especially when compared to the revised revenue guidance, and is driven by a $77.2 million non-cash impairment charge—suggesting a major write-down of assets or goodwill, which often signals management’s loss of confidence in the value of past investments or acquisitions. Stock price declines were immediate and severe: a drop of more than 24% (from $26.44 to $20.05) after the June guidance cut, followed by another nearly 26% plunge (from $17.47 to $12.97) after the July loss disclosure, indicating that the market was both surprised and deeply concerned by the magnitude of the problems. There is no evidence that prior targets or guidance were met; in fact, the company missed its own projections within a single quarter. The financial disclosures are specific for the items presented—guidance, net loss, impairment, and stock price—but lack broader context such as cash flow, liquidity, or operational metrics, making it impossible to assess the company’s ongoing viability or turnaround prospects. No information is provided about cost structure, customer retention, or pipeline health. An independent analyst, looking only at these numbers, would conclude that Simulations Plus is in crisis: revenue is falling, losses are ballooning, and the company’s auditor has walked away citing unresolved internal control issues. The absence of management commentary or a remediation plan further undermines confidence.

Analysis

The announcement is a law firm press release summarizing negative financial developments at Simulations Plus, Inc., including sharply reduced revenue guidance, a large net loss, and auditor dismissal. The tone is factual and negative, with no promotional or exaggerated language. Most claims are realised and supported by specific numerical disclosures (e.g., revenue guidance, net loss, impairment charge, stock price declines). Only a small fraction of statements are forward-looking, and these are limited to revenue guidance updates, which are standard and not aspirational. There is no evidence of narrative inflation or overstatement; the language is proportionate to the disclosed facts. No large capital outlay is paired with long-dated, uncertain returns, and the impairment charge is non-cash. The gap between narrative and evidence is minimal, as the release simply reports adverse events.

Risk flags

• ●Operational risk is acute: the company’s abrupt revenue guidance cut and massive impairment charge suggest that core business operations are under severe stress, with little visibility into stabilisation or recovery. This matters because operational instability can quickly erode customer trust and future revenue streams.
• ●Financial risk is high: a $67.3 million net loss in a single quarter, driven by a $77.2 million impairment, raises questions about the sustainability of the company’s capital structure and the true value of its assets. Investors face the risk of further write-downs or even liquidity crises if losses persist.
• ●Disclosure risk is significant: the company provides only partial financial data—no cash flow, balance sheet, or operational metrics—making it impossible for investors to fully assess solvency, runway, or the likelihood of further negative surprises. Incomplete disclosures often precede further adverse events.
• ●Governance risk is elevated: the dismissal of Grant Thornton LLP as auditor, coupled with the auditor’s public statement that internal control and reporting issues were unresolved, signals potential weaknesses in oversight, compliance, and financial integrity. This can lead to regulatory scrutiny, restatements, or even litigation.
• ●Pattern-based risk is evident: the company missed its own revenue guidance within a single quarter, indicating either poor forecasting, rapidly deteriorating market conditions, or both. This pattern undermines management credibility and suggests that future guidance, if provided, may also be unreliable.
• ●Timeline/execution risk is extreme: with no corrective actions or turnaround plan disclosed, investors have no basis to estimate when, or if, the company might recover. Any investment thesis based on a rebound is purely speculative at this stage.
• ●Legal risk is present: the ongoing investigation by Johnson Fistel, PLLP into potential securities law violations could result in costly litigation, settlements, or regulatory penalties, further eroding shareholder value.
• ●Market risk is amplified: the company attributes its problems to broader pharmaceutical and biotech market uncertainties, but provides no data to support this claim or to show that its issues are not company-specific. If the problems are internal, sector recovery will not necessarily help.

Bottom line

For investors, this announcement signals a company in deep distress, with immediate and material financial, operational, and governance problems. The narrative is credible only in the sense that it is supported by hard numbers—revenue guidance cuts, a massive net loss, and a public auditor dispute—but it is also incomplete, as there is no management response, no plan, and no evidence of stabilisation. No notable institutional figures or strategic investors are involved; the only named parties are from the investigating law firm and investor relations, offering no comfort or signal of external confidence. To change this assessment, the company would need to disclose a detailed turnaround plan, full financial statements, and evidence of restored auditor confidence and internal controls. Key metrics to watch in the next reporting period include updated revenue guidance, cash flow, liquidity, customer retention, and any new auditor’s opinion. At present, this is not a signal to buy or even to bottom-fish; it is a clear warning to monitor from the sidelines until credible evidence of recovery emerges. The most important takeaway is that Simulations Plus is facing a multi-front crisis—financial, operational, and governance—with no visible path to near-term recovery, and investors should exercise maximum caution.

Announcement summary

(NASDAQ:SLP) — Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. or certain of its executive officers violated federal securities laws. On April 3, 2025, Simulations Plus reported second-quarter fiscal 2025 financial results and maintained full-year fiscal 2025 revenue guidance of $90 million to $93 million. On June 11, 2025, Simulations Plus announced preliminary third-quarter fiscal 2025 revenue results and reduced its full-year fiscal 2025 revenue guidance to $76 million to $80 million. The Company disclosed a net loss of $67.3 million, or $3.35 per diluted share, for the third quarter of fiscal 2025, which included a $77.2 million non-cash impairment charge. Following these announcements, Simulations Plus stock declined more than 24%, falling from $26.44 per share to $20.05 per share, and then nearly 26%, declining from $17.47 per share to $12.97 per share. The Company’s Audit Committee dismissed Grant Thornton LLP as the independent registered public accounting firm, and Grant Thornton stated that certain matters relating to segment reporting, reporting-unit determinations, and internal control over financial reporting “were not resolved to our satisfaction” as of the date Grant Thornton was terminated. Johnson Fistel, PLLP recovered approximately $90,725,000 for investors in 2024.

Disagree with this article?